Immunoprecipitation Market by Product (Kit, Reagent (Antibodies, Magnetic Buffer)), Type (Individual IP, Coimmunoprecipitation, CHIP), End User (Academics, Research Institutes, Pharmaceutical and Biotechnology Companies) - Global Forecast to 2024

免疫沈降(IP)の世界市場予測(~2024年)

◆タイトル:Immunoprecipitation Market by Product (Kit, Reagent (Antibodies, Magnetic Buffer)), Type (Individual IP, Coimmunoprecipitation, CHIP), End User (Academics, Research Institutes, Pharmaceutical and Biotechnology Companies) - Global Forecast to 2024
◆商品コード:BT 6910
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年2月20日
◆ページ数:113
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオテクノロジー
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥604,550見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

免疫沈降の世界市場は、2018年の5億6,000万米ドルから2024年には7億5,000万米ドルに達し、この期間中5.0%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、ライフサイエンス業界における研究活動の増加と自己免疫疾患に関連する抗原を同定する(疾患メカニズムを理解し、これらの疾患を標的とする関連薬物を開発するための抗原抗体反応を用いる)必要性の高まりが考えられます。一方で、タンパク質精製のための代替技術の存在は市場の成長を妨げる可能性があります。当調査レポートでは、免疫沈降(IP)の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、製品(キット、試薬)分析、種類(単独IP、共免疫沈降、ChIP)分析、エンドユーザー(学術機関、研究機関、製薬会社・バイオテクノロジー企業)分析、免疫沈降(IP)の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

・イントロダクション
・エグゼクティブサマリー
・免疫沈降(IP)の世界市場:市場インサイト
・免疫沈降(IP)の世界市場:市場概観/市場動向
・免疫沈降(IP)の世界市場:製品(キット、試薬)分析/市場規模
・免疫沈降(IP)の世界市場:種類(単独IP、共免疫沈降、ChIP)分析/市場規模
・免疫沈降(IP)の世界市場:エンドユーザー(学術機関、研究機関、製薬会社・バイオテクノロジー企業)分析/市場規模
・免疫沈降(IP)のアジア市場規模予測
・免疫沈降(IP)のヨーロッパ市場規模予測
・免疫沈降(IP)のアメリカ市場規模予測
・免疫沈降(IP)の世界市場動向
・免疫沈降(IP)の世界市場:競争状況
・免疫沈降(IP)の世界市場:関連企業分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

“Increasing research activity in the life sciences industry is expected to drive the overall growth of the immunoprecipitation market.”The immunoprecipitation market is projected to reach USD 750 million by 2024 from USD 560 million in 2018, at CAGR of 5.0% during forecast period. The growth of this market is majorly driven by the increasing number of research activities in the life sciences industry and the growing need to identify antigens associated with autoimmune diseases (through antigen-antibody interaction to understand disease mechanisms and develop relevant drugs targeting these diseases). However, the presence of alternative technologies for protein purification is expected to restrain the growth of this market in the coming years.

“The kits segment is expected to grow at the highest CAGR during the forecast period.”
The immunoprecipitation market, by product, has been categorized into three major segments— kits, reagents, and accessories. The kits segment is estimated to grow at the highest CAGR from 2018 to 2024. The need for repeat purchase of kits, coupled with the increasing number of IP assays to isolate and purify antigens, forms a major driver for the growth of this segment.
“The pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period.”
The immunoprecipitation market, by end user, has been categorized into three major segments—academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations (CROs). The pharmaceutical & biotechnology companies segment is estimated to grow at the highest CAGR from 2018 to 2024. The increasing demand for protein-based drugs to drive the demand for immunoprecipitation in this end-user segment will support market growth.
“Asia Pacific projected to grow at the highest CAGR during the forecast period.”
In the immunoprecipitation market, Asia Pacific is projected to record the highest growth during the forecast period. China, Japan, and India are the major markets for immunoprecipitation in the Asia Pacific. Increasing investments by governments and industries, growing biotechnology research in these regions, and rising awareness about personalized therapeutics are expected to drive the growth of these markets during the forecast period.
In-depth interviews were conducted with Chief Executive Officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the immunoprecipitation market.
By Company Type: Tier 1–48%, Tier 2–34%, and Tier 3–18%
By Designation: C-level Executives–42%, Directors–40%, and Others–18%
By Region: North America–38%, Europe–25%, APAC–30%, and RoW–7%

The immunoprecipitation market comprises major providers such as Thermo Fisher Scientific (US), Abcam (UK), Merck KGaA (Germany). The study includes an in-depth competitive analysis of these key players in the immunoprecipitation market, along with their company profiles, recent developments, and key market strategies.
Research Coverage:
The market study covers the immunoprecipitation market across various segments. It aims at estimating the market size and the growth potential of this market across different segments, on the basis of product, analyte type, product, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall immunoprecipitation market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, and opportunities.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 MARKET SCOPE 13
1.3.1 MARKETS COVERED 14
1.3.2 YEARS CONSIDERED FOR THE STUDY 15
1.4 CURRENCY 15
1.5 STAKEHOLDERS 15
1.6 LIMITATIONS 15
2 RESEARCH METHODOLOGY 16
2.1 RESEARCH APPROACH 16
2.1.1 SECONDARY RESEARCH 17
2.1.1.1 Key data from secondary sources 17
2.1.2 PRIMARY RESEARCH 18
2.1.2.1 Key data from primary sources 18
2.1.2.2 Break down of primaries 19
2.1.2.3 Key industry insights 19
2.2 MARKET SIZE ESTIMATION 20
2.3 DATA TRIANGULATION APPROACH 22
2.4 ASSUMPTIONS FOR THE STUDY 23
3 EXECUTIVE SUMMARY 24
4 PREMIUM INSIGHTS 27
4.1 IMMUNOPRECIPITATION: MARKET OVERVIEW 27
4.2 IMMUNOPRECIPITATION MARKET, BY PRODUCT (2018–2024) 28
4.3 NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY TYPE (2018) 29
5 MARKET OVERVIEW 30
5.1 INTRODUCTION 30
5.2 MARKET DYNAMICS 30
5.2.1 MARKET DRIVERS 31
5.2.1.1 Increasing number of life sciences research activities 31
5.2.1.2 Growing need to identify antigens that are associated with autoimmune diseases 32
5.2.2 RESTRAINTS 32
5.2.2.1 Presence of alternative technologies 32
5.2.3 OPPORTUNITIES 32
5.2.3.1 Increasing focus on biomarker discovery 32
5.2.4 CHALLENGES 33
5.2.4.1 Quality concerns over research antibodies 33
6 IMMUNOPRECIPITATION MARKET, BY TYPE 34
6.1 INTRODUCTION 35
6.2 INDIVIDUAL IMMUNOPRECIPITATION 35
6.2.1 INCREASING DEMAND FOR BIOLOGICS IS DRIVING THE GROWTH OF THE MARKET 35
6.3 CO-IMMUNOPRECIPITATION 36
6.3.1 INCREASING USE OF CO-IP TO STUDY PROTEIN COMPLEXES FORMS A KEY MARKET DRIVER 36
6.4 CHROMATIN IMMUNOPRECIPITATION 37
6.4.1 GROWING ADOPTION OF HIGH-THROUGHPUT TECHNOLOGIES WILL CONTRIBUTE TO ADOPTION OF CHIP 37
6.5 RNA IMMUNOPRECIPITATION 38
6.5.1 AVAILABILITY OF GOVERNMENT FUNDING WILL DRIVE THE ADOPTION OF RIP KITS 38
7 IMMUNOPRECIPITATION MARKET, BY PRODUCT 40
7.1 INTRODUCTION 41
7.2 KITS 41
7.2.1 KITS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE IMMUNOPRECIPITATION MARKET DURING THE FORECAST PERIOD 41
7.3 REAGENTS 42
7.3.1 ANTIBODIES 43
7.3.1.1 Antibodies, by type 44
7.3.1.1.1 Primary Antibodies 45
7.3.1.1.1.1 Primary antibodies to account for the largest share of the immunoprecipitation antibodies market during the forecast period 45
7.3.1.1.2 Secondary Antibodies 46
7.3.1.1.2.1 Low cost of production – A major factor driving the growth of the secondary antibodies market 46
7.3.2 BEADS 47
7.3.2.1 Beads, by type 48
7.3.2.2 Agarose beads 48
7.3.2.2.1 High binding capacity and lower cost – Factors supporting the wide use of agarose beads in research laboratories 48
7.3.2.3 Magnetic beads 49
7.3.2.3.1 Magnetic bead-based separation helps increase throughput and reduces hands-on time 49
7.3.2.4 Buffers 50
7.3.2.4.1 Buffer solutions play an important role in maintaining pH balance in IP assays 50
7.4 ACCESSORIES 52
8 IMMUNOPRECIPITATION MARKET, BY END USER 53
8.1 INTRODUCTION 54
8.2 ACADEMIC & RESEARCH INSTITUTES 54
8.2.1 ACADEMIC & RESEARCH INSTITUTES ARE THE LARGEST END USERS OF IMMUNOPRECIPITATION 54
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 55
8.3.1 INCREASING DEMAND FOR PROTEIN-BASED DRUGS TO DRIVE THE DEMAND FOR IMMUNOPRECIPITATION IN THIS END-USER SEGMENT 55
8.4 CONTRACT RESEARCH ORGANIZATIONS 57
8.4.1 GROWTH IN OUTSOURCING OF PROTEIN PURIFICATION ACTIVITIES – A MAJOR FACTOR DRIVING THE DEMAND FOR IMMUNOPRECIPITATION TECHNOLOGIES IN CONTRACT RESEARCH ORGANIZATIONS 57
9 IMMUNOPRECIPITATION MARKET, BY REGION 59
9.1 INTRODUCTION 60
9.2 NORTH AMERICA 61
9.2.1 US 64
9.2.1.1 Growing research will drive market growth 64
9.2.2 CANADA 67
9.2.2.1 Increasing genomics and proteomics research to drive the adoption of immunoprecipitation in the coming years 67
9.3 EUROPE 70
9.3.1 GROWTH OF THE LIFE SCIENCES SECTOR WILL SUPPORT THE DEMAND FOR IMMUNOPRECIPITATION 70
9.4 ASIA PACIFIC 72
9.4.1 INCREASING DEMAND FOR NOVEL ANTIBODY AND PROTEIN-BASED DRUGS SUPPORT MARKET GROWTH IN THE ASIA PACIFIC 72
9.5 REST OF THE WORLD 76
10 COMPETITIVE LANDSCAPE 79
10.1 OVERVIEW 79
10.2 VENDOR BENCHMARKING 79
10.3 COMPETITIVE LEADERSHIP MAPPING 79
10.3.1 VISIONARY LEADERS 79
10.3.2 INNOVATORS 79
10.3.3 DYNAMIC DIFFERENTIATORS 79
10.3.4 EMERGING COMPANIES 79
10.4 MARKET RANKING ANALYSIS, 2017 81
10.5 COMPETITIVE SITUATION AND TRENDS 82
10.5.1 EXPANSIONS 82
10.5.2 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS 83
10.5.3 PRODUCT LAUNCHES 84
10.5.4 ACQUISITIONS 84
11 COMPANY PROFILES 85
(Business overview, Products offered, Recent Developments, MNM view)*
11.1 THERMO FISHER SCIENTIFIC 85
11.2 ABCAM 88
11.3 GENSCRIPT 90
11.4 MERCK KGAA 92
11.5 BIO-RAD LABORATORIES 95
11.6 BIOLEGEND 97
11.7 TAKARA BIO 100
11.8 ROCKLAND IMMUNOCHEMICALS 102
11.9 CELL SIGNALING TECHNOLOGY 103
11.10 GENO TECHNOLOGY 106
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX 107
12.1 DISCUSSION GUIDE 107
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 110
12.3 AVAILABLE CUSTOMIZATIONS 112
12.4 RELATED REPORTS 112
12.5 AUTHOR DETAILS 113

LIST OF TABLES

TABLE 1 IMMUNOPRECIPITATION MARKET, BY TYPE, 2016–2024 (USD MILLION) 35
TABLE 2 INDIVIDUAL IMMUNOPRECIPITATION MARKET, BY REGION,
2016–2024 (USD MILLION) 35
TABLE 3 NORTH AMERICA: INDIVIDUAL IMMUNOPRECIPITATION MARKET,
BY COUNTRY, 2016–2024 (USD MILLION) 36
TABLE 4 CO-IMMUNOPRECIPITATION MARKET, BY REGION, 2016–2024 (USD MILLION) 36
TABLE 5 NORTH AMERICA: CO-IMMUNOPRECIPITATION MARKET, BY COUNTRY,
2016–2024 (USD MILLION) 37
TABLE 6 CHROMATIN IMMUNOPRECIPITATION MARKET, BY REGION,
2016–2024 (USD MILLION) 37
TABLE 7 NORTH AMERICA: CHROMATIN IMMUNOPRECIPITATION MARKET,
BY COUNTRY, 2016–2024 (USD MILLION) 38
TABLE 8 RNA IMMUNOPRECIPITATION MARKET, BY REGION, 2016–2024 (USD MILLION) 38
TABLE 9 NORTH AMERICA: RNA IMMUNOPRECIPITATION MARKET, BY COUNTRY,
2016–2024 (USD MILLION) 39
TABLE 10 IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016–2024 (USD MILLION) 41
TABLE 11 IMMUNOPRECIPITATION KITS MARKET, BY REGION, 2016–2024 (USD MILLION) 41
TABLE 12 NORTH AMERICA: IMMUNOPRECIPITATION KITS MARKET, BY COUNTRY,
2016–2024 (USD MILLION) 42
TABLE 13 IMMUNOPRECIPITATION REAGENTS MARKET, BY REGION,
2016–2024 (USD MILLION) 42
TABLE 14 NORTH AMERICA: IMMUNOPRECIPITATION REAGENTS MARKET,
BY COUNTRY, 2016–2024 (USD MILLION) 43
TABLE 15 IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE,
2016–2024 (USD MILLION) 43
TABLE 16 IMMUNOPRECIPITATION ANTIBODIES MARKET, BY REGION,
2016–2024 (USD MILLION) 44
TABLE 17 NORTH AMERICA: IMMUNOPRECIPITATION ANTIBODIES MARKET,
BY COUNTRY, 2016–2024 (USD MILLION) 44
TABLE 18 IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE,
2016–2024 (USD MILLION) 44
TABLE 19 IMMUNOPRECIPITATION MARKET FOR PRIMARY ANTIBODIES, BY REGION,
2016–2024 (USD MILLION) 45
TABLE 20 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2016–2024 (USD MILLION) 45
TABLE 21 IMMUNOPRECIPITATION MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2016–2024 (USD MILLION) 46
TABLE 22 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2016–2024 (USD MILLION) 46
TABLE 23 IMMUNOPRECIPITATION BEADS MARKET, BY REGION, 2016–2024 (USD MILLION) 47
TABLE 24 NORTH AMERICA: IMMUNOPRECIPITATION BEADS MARKET, BY COUNTRY,
2016–2024 (USD MILLION) 47
TABLE 25 IMMUNOPRECIPITATION BEADS MARKET, BY TYPE, 2016–2024 (USD MILLION) 48
TABLE 26 IMMUNOPRECIPITATION MARKET FOR AGAROSE BEADS, BY REGION,
2016–2024 (USD MILLION) 49
TABLE 27 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR AGAROSE BEADS,
BY COUNTRY, 2016–2024 (USD MILLION) 49
TABLE 28 IMMUNOPRECIPITATION MARKET FOR MAGNETIC BEADS, BY REGION,
2016–2024 (USD MILLION) 50
TABLE 29 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR MAGNETIC BEADS,
BY COUNTRY, 2016–2024 (USD MILLION) 50
TABLE 30 IMMUNOPRECIPITATION BUFFERS MARKET, BY REGION,
2016–2024 (USD MILLION) 51
TABLE 31 NORTH AMERICA: IMMUNOPRECIPITATION BUFFERS MARKET, BY COUNTRY, 2016–2024 (USD MILLION) 51
TABLE 32 IMMUNOPRECIPITATION ACCESSORIES MARKET, BY REGION,
2016–2024 (USD MILLION) 52
TABLE 33 NORTH AMERICA: IMMUNOPRECIPITATION ACCESSORIES MARKET,
BY COUNTRY, 2016–2024 (USD MILLION) 52
TABLE 34 IMMUNOPRECIPITATION MARKET, BY END USER, 2016–2024 (USD MILLION) 54
TABLE 35 IMMUNOPRECIPITATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2016–2024 (USD MILLION) 55
TABLE 36 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016–2024 (USD MILLION) 55
TABLE 37 IMMUNOPRECIPITATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2016–2024 (USD MILLION) 56
TABLE 38 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2016–2024 (USD MILLION) 56
TABLE 39 IMMUNOPRECIPITATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY REGION, 2016–2024 (USD MILLION) 57
TABLE 40 NORTH AMERICA: IMMUNOPRECIPITATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016–2024 (USD MILLION) 58
TABLE 41 IMMUNOPRECIPITATION MARKET, BY REGION, 2016–2024 (USD MILLION) 60
TABLE 42 NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY COUNTRY,
2016–2024 (USD MILLION) 62
TABLE 43 NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY PRODUCT,
2016–2024 (USD MILLION) 62
TABLE 44 NORTH AMERICA: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE,
2016–2024 (USD MILLION) 62
TABLE 45 NORTH AMERICA: IMMUNOPRECIPITATION ANTIBODIES MARKET,
BY TYPE, 2016–2024 (USD MILLION) 63
TABLE 46 NORTH AMERICA: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE,
2016–2024 (USD MILLION) 63
TABLE 47 NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY TYPE,
2016–2024 (USD MILLION) 63
TABLE 48 NORTH AMERICA: IMMUNOPRECIPITATION MARKET, BY END USER,
2016–2024 (USD MILLION) 64
TABLE 49 US: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016–2024 (USD MILLION) 65
TABLE 50 US: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE,
2016–2024 (USD MILLION) 65
TABLE 51 US: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE,
2016–2024 (USD MILLION) 65
TABLE 52 US: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE,
2016–2024 (USD MILLION) 66
TABLE 53 US: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016–2024 (USD MILLION) 66
TABLE 54 US: IMMUNOPRECIPITATION MARKET, BY END USER, 2016–2024 (USD MILLION) 66
TABLE 55 CANADA: IMMUNOPRECIPITATION MARKET, BY PRODUCT,
2016–2024 (USD MILLION) 67
TABLE 56 CANADA: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE,
2016–2024 (USD MILLION) 68
TABLE 57 CANADA: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE,
2016–2024 (USD MILLION) 68
TABLE 58 CANADA: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE,
2016–2024 (USD MILLION) 68
TABLE 59 CANADA: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016–2024 (USD MILLION) 69
TABLE 60 CANADA: IMMUNOPRECIPITATION MARKET, BY END USER,
2016–2024 (USD MILLION) 69
TABLE 61 EUROPE: IMMUNOPRECIPITATION MARKET, BY PRODUCT,
2016–2024 (USD MILLION) 70
TABLE 62 EUROPE: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE,
2016–2024 (USD MILLION) 71
TABLE 63 EUROPE: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE,
2016–2024 (USD MILLION) 71
TABLE 64 EUROPE: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE,
2016–2024 (USD MILLION) 71
TABLE 65 EUROPE: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016–2024 (USD MILLION) 72
TABLE 66 EUROPE: IMMUNOPRECIPITATION MARKET, BY END USER,
2016–2024 (USD MILLION) 72
TABLE 67 ASIA PACIFIC: IMMUNOPRECIPITATION MARKET, BY PRODUCT,
2016–2024 (USD MILLION) 74
TABLE 68 ASIA PACIFIC: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE,
2016–2024 (USD MILLION) 74
TABLE 69 ASIA PACIFIC: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE,
2016–2024 (USD MILLION) 74
TABLE 70 ASIA PACIFIC: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE,
2016–2024 (USD MILLION) 75
TABLE 71 ASIA PACIFIC: IMMUNOPRECIPITATION MARKET, BY TYPE,
2016–2024 (USD MILLION) 75
TABLE 72 ASIA PACIFIC: IMMUNOPRECIPITATION MARKET, BY END USER,
2016–2024 (USD MILLION) 75
TABLE 73 ROW: IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2016–2024 (USD MILLION) 76
TABLE 74 ROW: IMMUNOPRECIPITATION REAGENTS MARKET, BY TYPE,
2016–2024 (USD MILLION) 76
TABLE 75 ROW: IMMUNOPRECIPITATION ANTIBODIES MARKET, BY TYPE,
2016–2024 (USD MILLION) 77
TABLE 76 ROW: IMMUNOPRECIPITATION BEADS MARKET, BY TYPE,
2016–2024 (USD MILLION) 77
TABLE 77 ROW: IMMUNOPRECIPITATION MARKET, BY TYPE, 2016–2024 (USD MILLION) 77
TABLE 78 ROW: IMMUNOPRECIPITATION MARKET, BY END USER,
2016–2024 (USD MILLION) 78
TABLE 79 EXPANSIONS, 2016–2018 82
TABLE 80 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS, 2016–2018 83
TABLE 81 PRODUCT LAUNCHES, 2016–2018 84
TABLE 82 ACQUISITIONS, 2016-2018 84


LIST OF FIGURES

FIGURE 1 IMMUNOPRECIPITATION MARKET 14
FIGURE 2 RESEARCH DESIGN 16
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS,
AND REGION 19
FIGURE 4 BOTTOM-UP APPROACH 20
FIGURE 5 TOP-DOWN APPROACH 21
FIGURE 6 DATA TRIANGULATION METHODOLOGY 22
FIGURE 7 IMMUNOPRECIPITATION MARKET, BY PRODUCT, 2018 VS. 2024 (USD MILLION) 24
FIGURE 8 IMMUNOPRECIPITATION MARKET, BY TYPE, 2018 VS. 2024 (USD MILLION) 25
FIGURE 9 IMMUNOPRECIPITATION MARKET, BY END USER, 2018 VS. 2024 (USD MILLION) 25
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE IMMUNOPRECIPITATION MARKET 26
FIGURE 11 INCREASING NUMBER OF RESEARCH ACTIVITIES IN THE LIFE SCIENCES INDUSTRY IS A KEY DRIVER FOR THE IMMUNOPRECIPITATION MARKET 27
FIGURE 12 KITS TO CONTINUE TO DOMINATE THE IMMUNOPRECIPITATION MARKET IN 2024 28
FIGURE 13 INDIVIDUAL IP ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN IMMUNOPRECIPITATION MARKET IN 2018 29
FIGURE 14 IMMUNOPRECIPITATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 30
FIGURE 15 LIFE SCIENCES R&D SPENDING, GLOBAL VS. US (USD BILLION) 31
FIGURE 16 NORTH AMERICA: IMMUNOPRECIPITATION MARKET SNAPSHOT 61
FIGURE 17 ASIA PACIFIC: IMMUNOPRECIPITATION MARKET SNAPSHOT 73
FIGURE 18 IMMUNOPRECIPITATION MARKET (GLOBAL) COMPETITIVE LEADERSHIP
MAPPING, 2017 80
FIGURE 19 RANK OF COMPANIES IN THE GLOBAL IMMUNOPRECIPITATION MARKET, 2017 81
FIGURE 20 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 85
FIGURE 21 ABCAM: COMPANY SNAPSHOT 88
FIGURE 22 GENSCRIPT: COMPANY SNAPSHOT 90
FIGURE 23 MERCK KGAA: COMPANY SNAPSHOT 92
FIGURE 24 BIO-RAD LABORATORIES: COMPANY SNAPSHOT 95
FIGURE 25 TAKARA BIO: COMPANY SNAPSHOT 100


【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[免疫沈降(IP)の世界市場予測(~2024年)]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆